Format

Send to

Choose Destination
Foot Ankle Clin. 2016 Dec;21(4):771-776. doi: 10.1016/j.fcl.2016.07.009.

Vancouver Experience of Recombinant Human Platelet-Derived Growth Factor.

Author information

1
Department of Orthopedics, University of British Columbia, 560-1144 Burrard Street, Vancouver, British Columbia V6Z 2A5, Canada. Electronic address: asyounger@shaw.ca.
2
Department of Orthopedics, University of British Columbia, 1000-1200 Burrard Street, Vancouver, British Columbia V6Z 2C7, Canada.
3
Department of Orthopedics, University of British Columbia, 560-1144 Burrard Street, Vancouver, British Columbia V6Z 2A5, Canada.

Abstract

Joint arthrodesis utilizing autogenous bone graft remains the gold standard of treatment in fusion procedures of the foot and ankle. Graft harvest, however, has been associated with increased morbidity to patients as well as increased costs. With this in mind, multiple clinical studies have evaluated the efficacy of recombinant human platelet-derived growth factor (rh-PDGF-BB) with beta-tricalcium phosphate (B-TCP) to augment in foot and ankle arthrodesis with favorable results. These factors have led to the increased use of rh-PDGF-BB with B-TCP in Vancouver with good clinical results.

KEYWORDS:

Bone graft substitute; Foot and ankle arthrodesis; Fusion; PDGF, Platelet-derived growth factor; Recombinant human platelet-derived growth factor

PMID:
27871410
DOI:
10.1016/j.fcl.2016.07.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center